Royalty Pharma (RPD) Financial Statements
Royalty Pharma Financial Overview
Royalty Pharma's market cap is currently $34.67B. The company's EPS TTM is $2.41; its P/E ratio is 27.87; and it has a dividend yield of 1.32%. Royalty Pharma is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $1.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.38B | $ 2.26B | $ 2.35B | $ 2.24B | $ 2.29B |
| Gross Profit | $ 2.38B | $ 2.26B | $ 2.35B | $ 2.24B | $ 2.29B |
| Operating Income | $ 1.56B | $ 1.29B | $ 1.49B | $ 307.06M | $ 1.43B |
| EBITDA | $ 1.64B | $ 1.56B | $ 1.89B | $ 423.69M | $ 1.43B |
| Net Income | $ 770.95M | $ 858.98M | $ 1.13B | $ 42.83M | $ 619.73M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 637.50M | $ 1.77B | $ 1.23B | $ 2.43B | $ 2.80B |
| Total Assets | $ 19.62B | $ 18.22B | $ 16.38B | $ 16.81B | $ 17.52B |
| Total Debt | $ 8.95B | $ 7.61B | $ 6.14B | $ 7.12B | $ 7.10B |
| Net Debt | $ 8.33B | $ 6.68B | $ 5.66B | $ 5.41B | $ 5.56B |
| Total Liabilities | $ 9.91B | $ 7.88B | $ 6.30B | $ 7.29B | $ 7.27B |
| Stockholders' Equity | $ 6.48B | $ 6.95B | $ 6.53B | $ 5.63B | $ 5.78B |
| Cash Flow | |||||
| Free Cash Flow | $ 2.49B | $ 2.77B | $ 2.99B | $ 2.14B | $ 2.02B |
| Operating Cash Flow | $ 2.49B | $ 2.77B | $ 2.99B | $ 2.14B | $ 2.02B |
| Investing Cash Flow | $ -1.61B | $ -2.68B | $ -2.07B | $ -1.03B | $ -1.87B |
| Financing Cash Flow | $ -1.19B | $ 361.14M | $ -2.15B | $ -944.86M | $ 385.11M |
Currency in USD
